kCP replacement therapy exerted also additional beneficial systemic effects in cpKO treated mice, including prevention of iron accumulation and steatosis in liver, and the reduction of leptin circulating levels thus confirming previous indications on its capability to correct lipid dysregulation in ACP21. The gene discussed is LEP; the disease is steatosis.